Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.

Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Abstract Text:

    Current guidelines for treatment of chronic hepatitis B include hepatitis B e antigen (HBeAg) status, levels of hepatitis B virus (HBV) DNA, and serum alanine aminotransferase (ALT) values in the setting of either chronic hepatitis or cirrhosis. Based on findings from a prospective study of hepatitis B surface antigen (HBsAg)-positive patients, we determined whether these guidelines included patients who developed hepatocellular carcinoma (HCC) and who died of non-HCC liver-related complications. The criteria for treatment from four published guidelines were matched to a cohort of 369 HBsAg-positive patients enrolled in the study. During a mean follow-up of 84 months, 30 patients developed HCC and 37 died of non-HCC liver-related deaths. Using criteria for antiviral therapy as stated by the four guidelines, only 20%-60% of the patients who developed HCC, and 27%-70% of patients who died of non-HCC liver-related deaths would have been identified for antiviral therapy according to current treatment recommendations. If baseline serum albumin levels of 3.5 mg/dL or less or platelet counts of 130,000 mm(3) or less were added to criteria from the four treatment guidelines, then 89%-100% of patients who died of non-HCC liver-related complications, and 96%-100% of patients who developed HCC would have been identified for antiviral therapy. In addition, if basal core promoter T1762/A1764 mutants and precore A1896 mutants also were included, then 100% of patients who developed HCC would have been identified for treatment. CONCLUSION: This retrospective analysis showed that the current treatment guidelines for chronic hepatitis B excluded patients who developed serious liver-related complications.

    Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Publishing Authors By Initials

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Hepatology (Baltimore, Md.)

    VOLUME: 48

    Page Numbers: 1070-8

    Journal Abbreviation: Hepatology

    ISSN: 1527-3350

    DAY: 2

    MONTH: Oct

    YEAR: 2008

    Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8302946

    Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.

    AFFILIATION: The Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine at the University of California in Los Angeles, CA, USA. myrontong@hmri.org

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Hepatology

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News